Buprenorphine Microspheres High Drug Load Solvent System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current buprenorphine delivery methods face challenges such as low drug load, high initial burst release, and the use of toxic solvents, which affect patient compliance and the efficacy of sustained release formulations.
Innovation Solution
A sustained release microsphere formulation with a high buprenorphine drug load, utilizing a dispersed phase comprising an encapsulating polymer, a primary solvent, and a co-solvent to enhance solubility, mixed with an aqueous continuous phase to form microspheres with controlled release profiles, minimizing initial burst and optimizing drug encapsulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If traditional injectable polymer solutions are used to provide sustained release, then the release duration is extended, but toxic solvents such as N-methyl pyrolidone must be used which creates safety concerns
Solution Approach 1:
The patent changes the chemical parameters of the solvent system by replacing toxic solvents like N-methyl pyrolidone with safer alternatives such as ethyl acetate, isopropyl alcohol, or their mixtures. This parameter change maintains the sustained release functionality while eliminating toxicity concerns, achieving both extended duration and safety requirements
Solution Approach 2:
The patent employs biodegradable polymers that degrade into harmless byproducts, replacing permanent toxic solvent systems. The polymer matrix itself serves as the delivery vehicle that degrades over time, eliminating the need for persistent toxic solvents and providing a safe, self-limiting delivery system
2Duration of action of stationary object
If microsphere formulations are designed for sustained release, then the release duration is extended, but the drug load becomes too low (less than 2%) to be commercially viable
Solution Approach 1:
The patent optimizes physical parameters including polymer molecular weight, polymer-to-drug ratio, and solvent composition to simultaneously achieve high drug loading (2-50% by weight) and extended release duration. By carefully controlling these parameters, the formulation maintains commercial viability while providing sustained release therapy
Solution Approach 2:
The patent uses composite material systems combining biodegradable polymers with carefully selected solvent-co-solvent mixtures to create a matrix that can accommodate high drug loads while maintaining structural integrity for sustained release. The composite nature allows optimization of both loading capacity and release kinetics
3Reliability
If microsphere formulations are designed to maintain steady plasma concentration, then withdrawal symptoms are prevented, but the initial burst release is too high causing potential toxicity
Solution Approach 1:
The patent adjusts formulation parameters such as polymer concentration, molecular weight, and solvent composition to control the initial burst release. By optimizing these parameters, the formulation achieves a balanced release profile that minimizes initial burst while maintaining steady plasma concentrations during the sustained release phase, preventing both toxicity and withdrawal symptoms
Solution Approach 2:
The patent employs surface modification techniques and pre-treatment of the polymer matrix to reduce the initial burst release before administration. By preparing the formulation in advance with controlled surface properties, the initial harmful burst is minimized while the sustained release functionality is preserved
4Ease of manufacture
If additional polymer coating is applied to microspheres, then manufacturing difficulties are reduced, but the device complexity increases
Solution Approach 1:
The patent extracts the need for additional protective coatings by optimizing the core polymer matrix formulation to provide inherent stability and controlled release functionality. By removing the coating step, the patent simplifies the manufacturing process while maintaining or improving performance, eliminating unnecessary complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a high drug load of 20-50% with low initial burst release, improved solubility, and extended release durations, enhancing patient compliance and reducing toxicity concerns.
Implementation Method 1
a co-solvent capable of increasing the solubility of the buprenorphine relative to the dispersed phase
Implementation Method 2
wherein the dispersed phase may be mixed with the continuous phase to form the microsphere formulation
Data Source
AI summary
A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.